SCHEMBL5569008

SCHEMBL5569008

FC(F)(F)c1ccc(Nc2ncnc3ccccc23)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.72
EGFR P00533 5/20 0.72
HTT P42858 2/20 0.71
TSHR P16473 1/20 0.71
DAPK3 O43293 1/20 0.69
MAP4K4 O95819 1/20 0.69
ABL1 P00519 1/20 0.69
ERBB2 P04626 1/20 0.69
PIM1 P11309 1/20 0.69
PRKACA P17612 1/20 0.69
LTK P29376 1/20 0.69
MAPK8 P45983 1/20 0.69
CSNK1A1 P48729 1/20 0.69
RPS6KA3 P51812 1/20 0.69
LIMK1 P53667 1/20 0.69
MAP2K1 Q02750 1/20 0.69
ACVR1 Q04771 1/20 0.69
TYRO3 Q06418 1/20 0.69
MAP4K2 Q12851 1/20 0.69
ROCK1 Q13464 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22137832 0.92 KDR (0.76) ABCG2EGFRHTTTSHRDAPK3
SCHEMBL5740105 0.85 EGFR (0.69) ABCG2EGFRHTTTSHRRAB9A
SCHEMBL5741873 0.85 ABCG2 (0.69) ABCG2EGFRHTTTSHRDAPK3
SCHEMBL5569041 0.83 EGFR (0.75) ABCG2EGFRHTTDAPK3MAP4K4
SCHEMBL11088081 0.82 EGFR (0.69) ABCG2EGFRHTTTSHRDAPK3
SCHEMBL8920 0.82 EGFR (1.00) ABCG2EGFRHTTDAPK3MAP4K4
SCHEMBL29941271 0.82 EGFR (1.00) ABCG2EGFRHTTDAPK3MAP4K4
SCHEMBL30017318 0.81 KDR (0.71) ABCG2EGFRHTTTSHRDAPK3
Hydrochloric Acid SCHEMBL11085999 0.81 TSHR (0.70) ABCG2EGFRHTTTSHRDAPK3
SCHEMBL16330874 0.81 KDR (0.68) ABCG2EGFRHTTTSHRDAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT ABCG2 311/4885EGFR 1445/4885HTT 2700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.